Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy

Heart Disease

Volumn 3, Issue 5, 2001, Pages 326-332

  Kaplan, R C ^a   Frishman, W H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

C reactive protein; Cardiovascular disease; Epidemiology; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; AZITHROMYCIN; C REACTIVE PROTEIN; CYTOKINE; ETANERCEPT; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MATRIX METALLOPROTEINASE INHIBITOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE MARKER; HEART INFARCTION; HUMAN; PHENOTYPE; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0035213726     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200109000-00009     Document Type: Review

References (81)

1. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
2. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
3. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
4. Role of inflammation in coronary plaque disruption
5. Atherosclerosis: An inflammatory disease
6. Novel inflammatory markers of coronary risk: Theory versus practice
7. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity
8. Induction of interleukin 1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid
9. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
10. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
11. A new role for P-selectin in shear-induced platelet aggregation
12. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
13. Acute systemic inflammation impairs endothelium-dependent dilatation in humans
14. Inflammatory markers of coronary risk
15. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants
16. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial
17. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
18. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
19. Soluble P-selectin and the risk of future cardiovascular events
20. Evaluation of four automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications
21. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects
22. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women
23. Distinct risk profiles of early and advanced atherosclerosis: Prospective results from the Bruneck Study
24. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis
25. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease
26. Direct proinflammatory effect of C-reactive protein on human endothelial cells
27. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis
28. Complement and atherogenesis: Binding of CRP to degraded, nonoxidized LDL enhances complement activation
29. Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis
30. Expression of allograft inflammatory factor-1 is a marker of activated human vascular smooth muscle cells and arterial injury
31. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury
32. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans
33. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: Assessment and implications for epidemiology
34. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction
35. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients
36. Association of recurrent myocardial infarction with hemostatic factors: A prospective study
37. Haemostatic variables and the outcome of myocardial infarction
38. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project
39. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group
40. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption
41. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
42. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons
43. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
44. The association of plasma IL-6 levels with functional disability in community-dwelling elderly
45. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older person
46. Serum C-reactive protein and self-reported stroke: Findings from the Third National Health and Nutrition Examination Survey
47. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly
48. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?
49. Elevated C-reactive protein levels in overweight and obese adult
50. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome
51. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study
52. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men
53. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study
54. Long-term effects of pravastatin on plasma concentration of C-reactive protein
55. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats
56. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
57. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
58. Statins and the acute-phase response
59. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications. The Effect of alpha-tocopherol supplementation
60. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells
61. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
62. Hormone replacement therapy, inflammation, and hemostasis in elderly women
63. Hormone replacement therapy and increased plasma concentration of C-reactive protein
64. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study
65. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women
66. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease
67. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries
68. Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research
69. The role of infection in atherosclerosis and coronary artery disease: A new therapeutic target
70. Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis
71. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
72. Elevated Chlamydia pneumoniae anti-bodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction
73. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study
74. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study
75. Cytomegalovirus seropositivity and c-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease
76. Tumor necrosis factor-α: A mediator of disease progression in the failing human heart
77. Regression of left ventricular remodeling in chronic heart failure after treatment with ENBREL (etanercept p75 TNF receptor Fc fusion protein)
78. Safety and efficacy of ENBREL (etanercept) in the treatment of chronic heart failure
79. Treatment of experimental viral myocarditis with interleukin-10
80. The role of inflammation after acute stroke: Utility of pursuing anti-adhesion molecule therapy
81. The effect of a CD11/CD18 inhibitor (Hu23F2G) on infarct size following direct angioplasty: The HALT MI study